The Ministry of Health (MOH) has announced that new Integrated Shield Plan (IP) rider changes will take effect from April ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional ...

Amerigo Scientific launched a comprehensive portfolio of GMP-grade proteins tailored to accelerate the development and ...

Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...

Understanding what depression is – and what it is not – is often the first step toward relief.

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's ...

Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development.

Voyager Therapeutics, Inc. reported fourth-quarter 2025 results showing a net loss of US$27.43 million versus US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 ...

Three Vietnamese researchers in Hong Kong have solved a 20-year puzzle in molecular biology that could reshape how scientists ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravisPhase 2 TRITON trial of Descartes-08 in ...

CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery ...